Ozden Sanal

Ozden Sanal

Auto-generated profile, based on publicly available information

Ozden Sanal

Department of Pediatric Immunology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2012 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
OSOzden Sanal
Ozden Sanal
HJHuie Jing
Huie Jing
TOTuba Ozgur
Tuba Ozgur
DCDeniz Cagdas
Deniz Cagdas
DSDara M. Strauss-Albee
Dara M. Strauss-Albee
HSHelen C. Su
Helen C. Su

1 April 2007 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
OSOzden Sanal
Ozden Sanal
GTGulten Turkkani
Gulten Turkkani
FGFatma Gumruk
Fatma Gumruk
LYLeman Yel
Leman Yel
GSGulten Secmeer
Gulten Secmeer
FEFugen Ersoy
Fugen Ersoy
Interleukin-12 receptor beta-1 (IL-12Rβ1) defect is generally associated with selective susceptibility to weakly pathogenic mycobacteria and Salmonella species. Patients rarely experience infections caused by other organisms. We report a 5-year-old patient with IL-12Rβ1 deficiency who developed recurrent visceral leishmaniasis 6 months apart. The patient responded to lyposomal amphotericin B treatment reasonably well.

30 November 2011 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
OSOzden Sanal
Ozden Sanal
ITIlhan Tezcan
Ilhan Tezcan

1 July 2004 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
OSOzden Sanal
Ozden Sanal
FEFugen Ersoy
Fugen Ersoy
ITIlhan Tezcan
Ilhan Tezcan
AMAyse Metin
Ayse Metin
TTTuba Turul
Tuba Turul
LYLeman Yel
Leman Yel

1 January 2009 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
BTBetul Tavil
Betul Tavil
ÖSÖzden Sanal
Özden Sanal
TTTuba Turul
Tuba Turul
LYLeman Yel
Leman Yel
AGAytemiz Gurgey
Aytemiz Gurgey
FGFatma Gumruk
Fatma Gumruk
Persistent pure red cell aplasia can be a manifestation of parvovirus B19 infection in immunocompromised hosts. Failure of the humoral immune response to clear parvovirus B19 in such patients results in persistent pure red cell aplasia. The authors describe a child who had T-cell immunodeficiency and persistent pure red cell aplasia due to parvovirus B19 infection. Interestingly, they detected human parvovirus B19 genome by polymerase chain reaction (PCR) not in the peripheral blood, but in the bone marrow specimen of the patient. In their patient, T-cell immunodeficiency may have caused impaired B-cell activation and failure of effective humoral immune response to neutralize the virus. Additionally, before the diagnosis of pure red cell aplasia, IVIG treatment given at a dosage of 400 mg/kg/day with 3-week intervals may result in sufficient neutralization of peripheral blood parvovirus B19, whereas it may not be sufficient for the neutralization of parvovirus B19 genome in bone marrow. Thus, peripheral blood parvovirus B19 serology (IgM and IgG) and PCR were negative, whereas bone marrow aspiration sample was positive for parvovirus B19 PCR in this patient. Reticulocytopenia and severe anemia may warn the physicians of parvovirus B19 infection, especially in immunocompromised children. Diagnosis may require demonstration of absence of late erythroid precursors in the bone marrow as well as serologic testing and detection of parvovirus B19 genome by PCR in the serum and/or bone marrow samples of the patient.

1 March 2003
Verified
Journal Article
Closed access
TTTolga Fikret Tözüm
Tolga Fikret Tözüm
EBEzel Berker
Ezel Berker
FEFügen Ersoy
Fügen Ersoy
ITIihan Tezcan
Iihan Tezcan
OSOzden Sanal
Ozden Sanal